Abstract
The complete eradication of Chronic Myeloid Leukemia is still challenging even in the era of highly selective and potent BCR-ABL tyrosine kinase inhibitors (TKIs). The ‘Achilles heel’ of TKI-based CML therapy is the inability of TKI to effectively target CML stem cells. Several pathways have been described to induce TKI insensitiveness in quiescent CML stem cells. In this review, we will describe the BCR-ABL/HAUSP/PML/PTEN network, whose signaling mediators converge to regulate the function of the tumor suppressor PTEN. We will also highlight the pharmacological strategies to modulate PTEN functions in order to sustain CML stem cell eradication.
Keywords: PTEN, PML, HAUSP, BCR-ABL, chronic myeloid leukemia.
Current Drug Targets
Title:Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia
Volume: 18 Issue: 4
Author(s): Alessandro Morotti, Davide Torti, Giovanna Carra, Cristina Panuzzo, Sabrina Crivellaro, Riccardo Taulli, Carmen Fava, Angelo Guerrasio and Giuseppe Saglio
Affiliation:
Keywords: PTEN, PML, HAUSP, BCR-ABL, chronic myeloid leukemia.
Abstract: The complete eradication of Chronic Myeloid Leukemia is still challenging even in the era of highly selective and potent BCR-ABL tyrosine kinase inhibitors (TKIs). The ‘Achilles heel’ of TKI-based CML therapy is the inability of TKI to effectively target CML stem cells. Several pathways have been described to induce TKI insensitiveness in quiescent CML stem cells. In this review, we will describe the BCR-ABL/HAUSP/PML/PTEN network, whose signaling mediators converge to regulate the function of the tumor suppressor PTEN. We will also highlight the pharmacological strategies to modulate PTEN functions in order to sustain CML stem cell eradication.
Export Options
About this article
Cite this article as:
Morotti Alessandro, Torti Davide, Carra Giovanna, Panuzzo Cristina, Crivellaro Sabrina, Taulli Riccardo, Fava Carmen, Guerrasio Angelo and Saglio Giuseppe, Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia, Current Drug Targets 2017; 18 (4) . https://dx.doi.org/10.2174/1389450117666160608120527
DOI https://dx.doi.org/10.2174/1389450117666160608120527 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Biomarkers for Lung Adenocarcinoma: A Short Review
Current Cancer Therapy Reviews The Efficacy of Vitamin K, A Member Of Naphthoquinones in the Treatment of Cancer: A Systematic Review and Meta-Analysis
Current Cancer Drug Targets Hypoxia: Targeting the Tumour
Anti-Cancer Agents in Medicinal Chemistry Recent Patents Concerning Diagnostic and Therapeutic Applications of Aberrantly Methylated Sequences in Pancreatic Cancer
Recent Patents on DNA & Gene Sequences Protein Interaction Domains: Structural Features and Drug Discovery Applications (Part 2)
Current Medicinal Chemistry Analysis of Fish IL-1β and Derived Peptide Sequences Indicates Conserved Structures with Species-Specific IL-1 Receptor Binding: Implications for Pharmacological Design
Current Pharmaceutical Design New Antitumour Natural Products from Marine Red Algae: Covering the Period from 2003 to 2012
Mini-Reviews in Medicinal Chemistry Immunological Aspects of Adult T-Cell Leukemia/Lymphoma (ATLL), a Possible Neoplasm of Regulatory T-Cells
Current Immunology Reviews (Discontinued) Microarrays and Colon Cancer in the Road for Translational Medicine
Current Bioinformatics Natural Bio-Drugs as Matrix Metalloproteinase Inhibitors: New Perspectives on the Horizon?
Recent Patents on Anti-Cancer Drug Discovery N6-Isopentenyladenosine and its Analogue N6-Benzyladenosine Induce Cell Cycle Arrest and Apoptosis in Bladder Carcinoma T24 Cells
Anti-Cancer Agents in Medicinal Chemistry Malignancy in Common Variable Immune Deficiency: Report of Two Rare Cases of Gastrointestinal Malignancy and a Review of the Literature
Cardiovascular & Hematological Disorders-Drug Targets Metabolomics: A Revolution for Novel Cancer Marker Identification
Combinatorial Chemistry & High Throughput Screening Second-Generation Tyrosine Kinase Inhibitors as First-Line Treatment Strategy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients
Current Cancer Drug Targets Hypocholesterolemia
Current Vascular Pharmacology State of the Art in African Trypanosome Drug Discovery
Current Topics in Medicinal Chemistry Oral and Dental Considerations in the Management of Leukemic Children
Applied Clinical Research, Clinical Trials and Regulatory Affairs Can γH2AX be Used to Personalise Cancer Treatment?
Current Molecular Medicine Novel Classes of Dimer Antitumour Drug Candidates
Current Pharmaceutical Design Development Course and an Application Strategy for Induced Pluripotent Stem Cells in Regenerative Medicine
Current Stem Cell Research & Therapy